期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

MicroRNAs在肿瘤中的作用研究进展 被引量：4

Study Progress on Effect of MicroRNAs in Tumor
原文传递
导出
摘要 MicroRNAs(miRNAs)是一类由19～25个核苷酸组成的短小、非编码蛋白质的RNAs,广泛存在于真核生物中,主要通过与靶基因mRNA3'UTR上的互补区域结合,在转录后水平对其降解或翻译抑制调节基因的表达。miRNA异常的表达均会影响正常细胞的功能,导致功能失调,在白血病等肿瘤的发生发展等过程中扮演重要角色。miRNA在疾病进程中所起的作用已经成为当前研究的热点,能够调控癌症发生、发展、凋亡等多种进程,越来越多的研究证明miRAN在肿瘤中可能起类似癌基因和抑癌基因的作用,甚至在抗癌药物的耐药机制方面也起重要作用。 MicroRNAs（miRNAs） are class of 19-25 nucleotide short non-coding RNAs that extensively exist in eukaryote,which can interact with the 3′UTR of the target mRNAs to result in degradation of target mRNA or translation repression.Misexpression of miRNA has been linked to disruption of normal cellular functions,which results in various disorders including cancers such as leukemia.The function of miRNA in the procession of the disease have been a hot topic,which are highly related to cancer progression,including initiating,growth and apoptosis.miRNAs play critical roles in tumorigenesis,which functions either as tumor suppressors or as oncogenes.Furthermore,miRNAs are shown to be responsible for anti-cancer drug resistance.
作者 燕华 李卫
机构地区 广西医科大学第一附属医院儿科
出处 《实用儿科临床杂志》 CAS CSCD 北大核心 2012年第21期1683-1685,共3页 Journal of Applied Clinical Pediatrics
关键词 微RNAS 白血病 癌基因 抑癌基因 microRNA leukemia oncogene tumor suppressor
分类号 R730.2 [医药卫生—肿瘤]
  • 相关文献

参考文献1

  • 1CHEN Hong1,CHEN Qun2,FANG Ming3 & MI Yan1 1 The First Affiliated Hospital of Harbin Medical University,Harbin 150101,China,2 Harbin Acheng District People’s Hospital,Harbin 150300,China,3 Graduate Department of Harbin Medical University,Harbin 150001,China.microRNA-181b targets MLK2 in HL-60 cells[J].Science China(Life Sciences),2010,53(1):101-106. 被引量：20

二级参考文献38

  • 1Phelan D R,Price G,Liu Y F,et al.Activated JNK phosphorylates the c-terminal domain of MLK2 that is required for MLK2-induced apoptosis. Journal of Biological Chemistry . 2001
  • 2Bartel DP.MicroRNAs: genomics, biogenesis, mechanism and function. Cell . 2004
  • 3Tran SE,Holmstrom TH,Ahonen M,Kahari VM,Eriksson JE.MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. Journal of Biological Chemistry . 2001
  • 4Robinson MJ,Cobb MH.Mitogen-activated protein kinase pathways. Current Opinion in Cell Biology . 1997
  • 5Lowenberg B,Downing JR,Burnett A.Acute myeloid leukemia. New England Journal of Medicine, The . 1999
  • 6Whitman S P,Archer K J,Feng L,et al.Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Research . 2001
  • 7Xie X,Lu J,Kulbokas EJ,et al.Systematic discovery of regulatory motifs in human promoters and 3’UTRs by comparison of several mammals. Nature . 2005
  • 8Lewis B P,Burge C B,Bartel D P.Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell . 2005
  • 9Wheatley K,Burnett AK,Goldstone AH eta1.A simple,robust,validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukemia derivedfrom the MRC AML 10 trial.United Kingdom Medical Research Council‘ s Adult and Childhood Leukemia Working Parties. British Journal of Haematology . 1999
  • 10Kottaridis P D,Gale R E,Frew M E,et al.The presence ofa Flt-3internal tandem duplication in patients with acutemyeloid leukemia(AML)adds important prognosticinformation to cytogenetic risk group and response to the firstcycle of chemotherapy:. Blood . 2001

共引文献19

同被引文献50

  • 1Peng H,Yuan X,Shi R,et al.PHH-7 inhibits cell growth and induces apoptosis in leukemia cell line K562 as well as its MDR-counterpart K562/A02 through producing reactive oxygen species[J].Eur J Pharmacol,2013,718(1-3):459468.
  • 2Wang H,Wang X,Li Y,et al.The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway[J].Pharmazie,2012,67(2):187-192.
  • 3Zhang W,Chen BA,Jin JF,et al.Involvement of c-Jun N-terminal kinase in reversal of multidrug resistance of human leukemia cells in hypoxia by 5-bromotetrandrine[J].Leuk Lymphoma,2013,54(11):2506-2516.
  • 4Zhou H'Ma H,Wei W,et al.B4GALT family mediates the multidrug resistance of human leukemia cells by regulating the hedgehog path- way and the expression of p-glycoprotein and multidrug resistance-as- sociated protein I[J].Cell Death Dis,2013,4:e654.
  • 5Fenner KS,Troutman MD,Kempshall S,et al.Drug-drug interactions mediated through p-glycoprotein:clinical relevance and in vitro-in vi- vo correlation using digoxin as a probe drug[J].Clin Pharmacol T- her,2009,85(2):173-181.
  • 6Li X,Miao H,Zhang Y,et al.Bone marrow microenvironment con- fers imatinib resistance to chronic myelogenous leukemia and orxylin A reverses the resistance by suppressing Stat3 pathway[J].Arch Toxicol,2015,89(1):121-136.
  • 7Farawela HM,Khorshied MM,Kassem NMf et al.The clinical rele- vance and prognostic significance of adenosine triphosphate ATP- binding cassette(ABCB5)and multidrug resistance(MDRl)genes expression in acute leukemia?? an Egyptian study[J],J Cancer Res Clin Oncol,2014,140(8):1323-1330.
  • 8Wang L,Meng Q,Wang C,et al.Dioscin restores the activity of the anticancer agent adriamycin in multidrug-resistance human leukemia K562/adriamycin cells by down-regulating MDRl via a mechanism involving NF-kB signaling inhibition"].J Nat Prod,2013,76(5):909-914.
  • 9Shen H,Xu W,Chen Q,et al.Tetrandrine prevents acquired drug re- sistance of K562 cells through inhibition of mdrl gene transcription [J].J Cancer Res Clin Oncol,2010,136(5):659-665.
  • 10Feng DD,Zhang H,Zhang P,et,al.Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia[J].J Cell Mol Med,2011,15(10):2164-2175.

引证文献4

二级引证文献13

实用儿科临床杂志
2012年 第21期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部